Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients

  • Anna Kumor
  • Piotr Daniel
  • Mirosława Pietruczuk
  • Ewa Małecka-Panas
Original Article

Abstract

Introduction

Leptin, adiponectin, and resistin are the proteins secreted by adipocytes, which affects the metabolism. While the role of leptin in colon carcinogenesis is documented, the effect of adiponectin and resistin remains unclear. It has been indicated that while leptin may potentiate the cancer cells growth, adiponectin and resistin may act oppositely.

Aim

The aim of this study is to determine the concentration of leptin, adiponectin, and resistin in patients with adenomatous polyps and colorectal cancer.

Methods

The serum concentration investigated adipohormones had been measured with ELISA in 37 patients with colorectal adenomas, 36 with colorectal cancer (CC) and in 25 controls with no colorectal pathology. Endoscopically removed polyps and CC biopsies had been evaluated with histopathology. Mean BMI value was calculated for all patients.

Results

Among 37 adenomas, 25 revealed high-grade dysplasia (HGD) and 12 low-grade dysplasia (LGD). All cases of CC were adenocarcinomas. No difference in the level of investigated adipohormones in serum between patients with HGD and LGD polyps was observed. The serum concentration of leptin and adiponectin in CC patients was lower than in patients with adenomas (p < 0.05; p < 0.05, respectively) as well as in controls (p < 0.01; p < 0.05, respectively). The concentration of resistin in CC was not significantly different in the adenoma group (p > 0.05) but higher than in controls (p < 0.05). There was a correlation between adiponectin and leptin serum concentration (r = 0.61).

Conclusion

We conclude that serum concentration of adiponectin and resistin may play an important role in colon carcinogenesis. We also assume that leptin may possibly have the prognostic value useful in clinical practice and its concentration is independent of BMI value.

Keywords

Leptin Adiponectin Resistin Colorectal adenoma Colorectal cancer 

References

  1. 1.
    Arpaci F, Yilmaz MI, Ozet A et al (2002) Low serum leptin level in colon cancer patients without significant weight loss. Tumori 88(2):147–149PubMedGoogle Scholar
  2. 2.
    Baratta M (2002) Leptin—from a signal of adiposity to a hormone mediator in peripheral tissues. Med Sci Monit 8:RA282–RA292PubMedGoogle Scholar
  3. 3.
    Margetic S, Gazzola C, Pegg GG et al (2002) Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 26:1407–1433PubMedCrossRefGoogle Scholar
  4. 4.
    Mora S, Pessin JE (2002) An adipocentric view of signaling and intracellular trafficking. Diabetes Metab Res Rev 18:345–356PubMedCrossRefGoogle Scholar
  5. 5.
    Beltowski J (2003) Adiponectin and resistin—new hormones of white adipose tissue. Med Sci Monit 9:RA55–RA61PubMedGoogle Scholar
  6. 6.
    Rohner-Jeanrenaud F, Jeanrenaud B (1996) The discovery of leptin and its impact in the understanding of obesity. Eur J Endocrinol 135:649–650PubMedCrossRefGoogle Scholar
  7. 7.
    Friedman JM, Halaas J1 (1998) Leptin and the regulation of body weight in mammals. Nature 22:763–770CrossRefGoogle Scholar
  8. 8.
    Faraj M, Havel PJ, Phelis S et al (2003) Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 88:1594–1602PubMedCrossRefGoogle Scholar
  9. 9.
    Ukkola O (2002) Resistin—a mediator of obesity associated insulin resistance or an innocent bystander? Eur J Endocrinol 147:571–574PubMedCrossRefGoogle Scholar
  10. 10.
    Housa D, Housova J, Vernerova Z et al (2006) Adipocytokines and cancer. Physiol Res 55:233–244PubMedGoogle Scholar
  11. 11.
    Vendrell J, Broch M, Vilarrasa N et al (2004) Resistin, adiponectin, ghrelin, leptin and proinflammatory cytokines: relationships in obesity. Obes Res 12:962–971PubMedCrossRefGoogle Scholar
  12. 12.
    Bray GA (2002) The underlying basis for obesity: relationship to cancer. J Nutr 132:3451S–3455SPubMedGoogle Scholar
  13. 13.
    Jonsson F, Wolk A, Pedersen NL et al (2003) Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry. Int J Cancer 106:594–599PubMedCrossRefGoogle Scholar
  14. 14.
    Rohrmann S, Platz EA, Smit E et al (2004) Body size and serum level of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 172:779PubMedCrossRefGoogle Scholar
  15. 15.
    Tamakoshi K, Toyoshima H, Wakai K et al (2005) Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. Oncology 68(4–6):454–461PubMedCrossRefGoogle Scholar
  16. 16.
    Frezza EE, Wachtel MS, Chiriva-Internati M (2006) Influence of obesity on the risk of developing colon cancer. Gut 55(2):285–291PubMedCrossRefGoogle Scholar
  17. 17.
    Bolubkbas F, Kilic H, Bolukbas C et al (2004) Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study. BMC Cancer 4:29CrossRefGoogle Scholar
  18. 18.
    Tessitore L, Vizio B, Jenkins O et al (2000) Leptin expression in colorectal and breast cancer patients. Int J Mol Med 5(4):421–426PubMedGoogle Scholar
  19. 19.
    Arita Y, Kihara S, Ouchi M et al (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMedCrossRefGoogle Scholar
  20. 20.
    Hardwick JC, van Der Brink GR, Offerhause GJ (2001) Leptin is a growth factor for colonic epithelial cells. Gastroenterology 121(1):79–90PubMedCrossRefGoogle Scholar
  21. 21.
    Aparicio T, Kotelevets L, Tsocas A et al (2005) Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in APC(Min/+) mice. Gut 54(8):1136–1145PubMedCrossRefGoogle Scholar
  22. 22.
    Hamilton SR, Aaltonen LA (2000) WHO classification of tumors pathology and genetics. Tumors of the digestive system. IARC, LyonGoogle Scholar
  23. 23.
    Sobin LH, Wittekind C (2002) Classification of malignant tumors. Sixth editionGoogle Scholar
  24. 24.
    Simons JP, Schols AM, Campfirld LA et al (1997) Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond) 93:273–277Google Scholar
  25. 25.
    Wallace AM, Sattar N, McMillan DC (1998) Effect of weight loss and the inflammatory response on leptin concentration in gastrointestinal cancer patients. Clin Cancer Res 4:2977–2979PubMedGoogle Scholar
  26. 26.
    Frankenberry KA, Somasundar P, McFadden DW et al (2004) Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg 188:560–565PubMedCrossRefGoogle Scholar
  27. 27.
    Hardwick JC, van Der Brink GR, Offerhause GJ (2001) Leptin is a growth factor for colonic epithelial cells. Gastroenterology 121(1):79–90PubMedCrossRefGoogle Scholar
  28. 28.
    Garofalo C, Surmacz E (2005) Leptin and cancer. J Cell Physiol 207:12–22CrossRefGoogle Scholar
  29. 29.
    Vona-Davis L, Rose DP (2007) Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 14(2):189–206, JunPubMedCrossRefGoogle Scholar
  30. 30.
    Mistry T, Digby JE, Desai KM et al (2007) Obesity and prostate cancer: a role for adipokines. Eur Urol 52(1):46–53, JulPubMedCrossRefGoogle Scholar
  31. 31.
    Levy M, Visokai V, Lipska L et al (2008) Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma 55(2):138–142PubMedGoogle Scholar
  32. 32.
    Fukumoto J, Otake T, Tajima O et al (2008) Adiponectin and colorectal adenomas: self defense forces health study. Cancer Sci 99(4):781–786PubMedCrossRefGoogle Scholar
  33. 33.
    Ishikawa M, Kitayama J, Kazama S et al (2005) Plasma adiponectin and gastric cancer. Clin Cancer Res 11:466–472PubMedCrossRefGoogle Scholar
  34. 34.
    Wei E, Giovannucci E, Fuchs C et al (2005) Plasma adiponectin levels and risk of CC in men. JNCI 97(22):1688–1694PubMedGoogle Scholar
  35. 35.
    Wang B, Jenkins JR, Trayhurn P (2005) Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Integrated response to TNFα. Am J Physiol Endocrinol Metab 288:E731–E740PubMedCrossRefGoogle Scholar
  36. 36.
    Williams CJ, Mitsiades N, Sozopulos E et al (2008) Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocrine-rel Cancer 15:289–299CrossRefGoogle Scholar
  37. 37.
    Ogunwobi OO, Beales ILP (2008) Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Molecular Cell Endocr 285:43–50CrossRefGoogle Scholar
  38. 38.
    Lehrke M, Reilly MP, Millington SC et al (2004) An inflammatory cascade leading to hyperresistinemia in human. PLoS Med 1:161–168CrossRefGoogle Scholar
  39. 39.
    Silswal N, Singh AK, Aruna B et al (2005) Human resistin stimulates the pro-inflammatory cytokines TNF alpha and IL-12 in macrophages by NFkappaB dependent pathway. Biochem Biophys Res Commun 334:1092–1101PubMedCrossRefGoogle Scholar
  40. 40.
    Kang JH, Yu BY, Youn DS (2007) Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 22(1):117–121, FebPubMedGoogle Scholar
  41. 41.
    Konrad A, Lehrke M, Schachinger V et al (2007) Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 19(12):1070–1074, DecPubMedCrossRefGoogle Scholar
  42. 42.
    Karmiris K, Koutroubakis IE, Xidakis C et al (2006) Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 12(2):100–105, FebPubMedCrossRefGoogle Scholar
  43. 43.
    Mu H, Ohashi R, Yan S et al (2006) Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 70(1):146–157, Apr 1PubMedCrossRefGoogle Scholar
  44. 44.
    Calabro P, Samudio I, Willerson JT et al (2004) Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110(21):3335–3340, Nov 23PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Anna Kumor
    • 1
  • Piotr Daniel
    • 2
  • Mirosława Pietruczuk
    • 1
  • Ewa Małecka-Panas
    • 2
  1. 1.Department of Laboratory DiagnosticsMedical UniversityLodzPoland
  2. 2.Department of Digestive Tract DiseasesMedical UniversityLodzPoland

Personalised recommendations